CompletedNCT01041092
Raloxifene added to antipsychotic treatment for schizophrenia symptoms
About this title
Read the official source — NCT01041092This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.
Medication studyAges 40+Spain
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.
Who was this study for?
Listed age limits: from 40 years.
- Listed locations
- Esplugues de LlobregatSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- Fundació Sant Joan de Déu
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Spain
- Age range
- Over 40 Years
- Official registry ID
- NCT01041092
- Official title
Show the full official title
Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Esplugues de Llobregat
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.
Who is behind this study?
The study sponsor is Fundació Sant Joan de Déu.
Did this study involve medication?
Yes. The study involved medication, including raloxifene.
Who was this study for?
Listed age limits: from 40 years.
